Erich Mohr - Publications

Affiliations: 
MedGenesis Therapeutix Inc., Victoria, British Columbia, Canada 
Area:
Neurotherapeutics

82 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Luz M, Mohr E, Fibiger HC. GDNF-Induced cerebelllar toxicity: A brief Review. Neurotoxicology. PMID 26535469 DOI: 10.1016/j.neuro.2015.10.011  0.48
2014 Mohr E. Do We Need New Endpoints in Clinical Trials: Surrogate and Biomarkers Re-Engineering Clinical Trials: Best Practices For Streamlining the Development Process. 159-170. DOI: 10.1016/B978-0-12-420246-7.00015-3  0.48
2013 Taylor H, Barua N, Bienemann A, Wyatt M, Castrique E, Foster R, Luz M, Fibiger C, Mohr E, Gill S. Clearance and toxicity of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHu GDNF) following acute convection-enhanced delivery into the striatum. Plos One. 8: e56186. PMID 23526931 DOI: 10.1371/journal.pone.0056186  0.48
2011 Rosenbluth KH, Luz M, Mohr E, Mittermeyer S, Bringas J, Bankiewicz KS. Design of an in-dwelling cannula for convection-enhanced delivery. Journal of Neuroscience Methods. 196: 118-23. PMID 21187114 DOI: 10.1016/j.jneumeth.2010.12.022  0.48
2006 Jegoux F, Cazé A, Mohr E, Godey B, Le Clech G. [Neck dissection for stage N0 oral cavity carcinoma]. Annales D'Oto-Laryngologie Et De Chirurgie Cervico Faciale : Bulletin De La SociéTé D'Oto-Laryngologie Des HôPitaux De Paris. 123: 221-6. PMID 17185919  0.48
2005 Morel N, Dumas G, Nguyen DQ, Mohr E, Hitter A, Schmerber S. [Vestibular neurotomy versus chemical labyrinthectomy for disabling Menière disease]. Annales D'Oto-Laryngologie Et De Chirurgie Cervico Faciale : Bulletin De La SociéTé D'Oto-Laryngologie Des HôPitaux De Paris. 122: 271-80. PMID 16505777 DOI: 10.1016/S0003-438X(05)82361-8  0.48
2005 Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry. 20: 559-69. PMID 15920715 DOI: 10.1002/gps.1325  0.48
2004 Collins B, Constant J, Kaba S, Barclay CL, Mohr E. Dementia with lewy bodies: implications for clinical trials. Clinical Neuropharmacology. 27: 281-92. PMID 15613933 DOI: 10.1097/01.wnf.0000148388.56605.d9  0.48
2002 Engeland C, Mahoney C, Mohr E, Ilivitsky V, Knott V. Nicotine and sensory memory in Alzheimer's disease: an event-related potential study. Brain and Cognition. 49: 232-4. PMID 15259398  0.48
2002 Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics / Ipa. 14: 389-404. PMID 12670060 DOI: 10.1017/S104161020200858X  0.48
2002 Riffaud L, Mohr E, Morandi X, Godey B, Feat S, Brassier G. [Forestier disease presenting as dysphagia]. Presse MéDicale (Paris, France : 1983). 31: 1650-2. PMID 12448330  0.48
2002 Knott V, Mohr E, Mahoney C, Engeland C, Ilivitsky V. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. Neuropsychobiology. 45: 156-60. PMID 11979067 DOI: 10.1159/000054957  0.48
2002 Engeland C, Mahoney C, Mohr E, Ilivitsky V, Knott VJ. Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study. Pharmacology, Biochemistry, and Behavior. 72: 457-64. PMID 11900820 DOI: 10.1016/S0091-3057(02)00711-6  0.48
2001 Mohr E, Hildebrand K, Mendis T, De Deyn PP. Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications. Neurology. 56: 1249-50. PMID 11342706  0.48
2001 Knott V, Mohr E, Mahoney C, Ilivitsky V. Quantitative electroencephalography in Alzheimer's disease: comparison with a control group, population norms and mental status. Journal of Psychiatry & Neuroscience : Jpn. 26: 106-16. PMID 11291527  0.48
2000 Baladi JF, Bailey PA, Black S, Bouchard RW, Farcnik KD, Gauthier S, Kertesz A, Mohr E, Robillard A. Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications. Clinical Therapeutics. 22: 1549-61. PMID 11192146 DOI: 10.1016/S0149-2918(00)83053-2  0.48
2000 Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 1230-7. PMID 11104211 DOI: 10.1002/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9  0.48
2000 Knott V, Mohr E, Mahoney C, Ilivitsky V. Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease. Methods and Findings in Experimental and Clinical Pharmacology. 22: 115-22. PMID 10849895  0.48
2000 Knott V, Engeland C, Mohr E, Mahoney C, Ilivitsky V. Acute nicotine administration in Alzheimer's disease: an exploratory EEG study. Neuropsychobiology. 41: 210-20. PMID 10828731  0.48
2000 Knott V, Mohr E, Mahoney C, Ilivitsky V. Electroencephalographic coherence in Alzheimer's disease: comparisons with a control group and population norms. Journal of Geriatric Psychiatry and Neurology. 13: 1-8. PMID 10753001  0.48
1999 Knott V, Mohr E, Haché N, Mahoney C, Mendis T. EEG and the passive P300 in dementia of the Alzheimer type. Clinical Eeg (Electroencephalography). 30: 64-72. PMID 10358785  0.48
1998 Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology. 20: 310-9. PMID 9845158 DOI: 10.1076/jcen.20.3.310.823  0.48
1998 Willmer J, Mohr E. Evaluation of selection criteria used in Alzheimer's disease clinical trials. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 25: 39-43. PMID 9532279  0.48
1997 Mohr E, Claus JJ, Brouwers P. Basal ganglia disease and visuospatial cognition: Are there disease-specific impairments? Behavioural Neurology. 10: 67-75. PMID 24486746 DOI: 10.3233/BEN-1997-102-304  0.48
1997 Blesa R, Mohr E, Miletich RS, Randolph C, Hildebrand K, Sampson M, Chase TN. Changes in cerebral glucose metabolism with normal aging. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 4: 8-14. PMID 24283817 DOI: 10.1111/j.1468-1331.1997.tb00294.x  0.48
1997 Feldman H, Anand R, Blesa R, Dubois B, Gray J, Homma A, Mohr E, Morris JC, Parys W, Raschig A, Robillard A. Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders. 11: 61-4. PMID 9305520  0.48
1997 Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, Morris JC, Rogers S, Sawada T. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders. 11: 8-18. PMID 9305508  0.48
1997 Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, Mendis T. Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clinical Neuropharmacology. 20: 338-45. PMID 9260731  0.48
1997 Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Pryse-Phillips W, Gauthier S. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 24: 140-5. PMID 9164692  0.48
1997 Claus JJ, van Gool WA, Feldman H, Mohr E. SPECT in AD. Neurology. 48: 1139-40. PMID 9109925  0.48
1996 Mohr E, Walker D, Randolph C, Sampson M, Mendis T. Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. International Psychogeriatrics / Ipa. 8: 397-411. PMID 9116176 DOI: 10.1017/S1041610296002761  0.48
1996 Pappas BA, Davidson CM, Fortin T, Nallathamby S, Park GA, Mohr E, Wiley RG. 192 IgG-saporin lesion of basal forebrain cholinergic neurons in neonatal rats. Brain Research. Developmental Brain Research. 96: 52-61. PMID 8922668 DOI: 10.1016/0165-3806(96)00095-8  0.48
1996 Gauthier S, Montplaisir J, Petit D, Joanette Y, Feldman H, Mohr E, Nair NP, Poirier J. Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease. Alzheimer Disease and Associated Disorders. 10: 19-21. PMID 8876784  0.48
1996 Blesa R, Mohr E, Miletich RS, Hildebrand K, Sampson M, Chase TN. Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Dementia (Basel, Switzerland). 7: 239-45. PMID 8872413  0.48
1996 Claus JJ, Mohr E. Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurologica Scandinavica. 93: 346-51. PMID 8800345  0.48
1996 Brouwers P, Mohr E, Hildebrand K, Hendricks M, Claus JJ, Baron IS, Young M, Pierce P. A novel approach to the determination and characterization of HIV dementia. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 23: 104-9. PMID 8738921  0.48
1996 Latour P, Belaiche J, Louis E, Fontaine F, Deflandre J, Loly J, Oger A, Defrance P, Di Valentin A, Delforge M, Daenen G, Lebas M, Mohr E, Wain E, Gillard C, et al. Incidence of inflammatory bowel disease in the province of Liège (Belgium). La Société de Gastroentérologie Liègeoise. Acta Gastro-Enterologica Belgica. 59: 3-6. PMID 8686414  0.48
1996 McFadden L, Mohr E, Sampson M, Mendis T, Grimes JD. A profile analysis of demented and nondemented Parkinson's disease patients. Advances in Neurology. 69: 339-41. PMID 8615149  0.48
1996 Bastens B, Gast P, Delforge M, Mohr E, Jardon C, Abraham F, Moureau A, Demolin H, Belaiche J. Gastric antral vascular ectasia syndrome: clinical and endoscopic presentation and endoscopic treatment | Le syndrome des ectasies vasculaires antrales : présentation clinique, endoscopique et traitement endoscopique Acta Endoscopica. 26: 47-55. DOI: 10.1007/BF02969595  0.48
1996 Mendis T, Lynn Barclay C, Mohr E. Drug-induced psychosis in Parkinson's disease: A review of management Cns Drugs. 5: 166-174.  0.48
1995 Mohr E, Brouwers P, Claus JJ, Purdon SE, Gagnon M, Chase TN. Differential classification of dementia. Behavioural Neurology. 8: 23-30. PMID 24487399 DOI: 10.3233/BEN-1995-8103  0.48
1995 Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clinical Neuropharmacology. 18: 28-38. PMID 8665532  0.48
1995 Braun AR, Randolph C, Stoetter B, Mohr E, Cox C, Vladar K, Sexton R, Carson RE, Herscovitch P, Chase TN. The functional neuroanatomy of Tourette's syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 13: 151-68. PMID 8597526 DOI: 10.1016/0893-133X(95)00052-F  0.48
1995 Mohr E, Mendis T, Grimes JD. Late cognitive changes in Parkinson's disease with an emphasis on dementia. Advances in Neurology. 65: 97-113. PMID 7872155  0.48
1995 Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 22: 62-71. PMID 7750079  0.48
1995 Blesa R, Mohr E, Miletich RS, Chase TN. Limbic system dysfunction in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 59: 450-1. PMID 7561934 DOI: 10.1136/jnnp.59.4.450-a  0.48
1994 Mendis T, Mohr E, George A, Rusk IN, Gray P, Grimes JD. Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 197-200. PMID 8196683 DOI: 10.1002/mds.870090213  0.48
1994 McFadden L, Sampson M, Mohr E. Screening for cognitive dysfunction in neurodegenerative illness. Journal of Neurology, Neurosurgery, and Psychiatry. 57: 1282. PMID 7931408 DOI: 10.1136/jnnp.57.10.1282  0.48
1994 Mohr E, Mendis T, Rusk IN, Grimes JD. Neurotransmitter replacement therapy in Alzheimer's disease. Journal of Psychiatry & Neuroscience : Jpn. 19: 17-23. PMID 7908537  0.48
1994 Purdon SE, Mohr E, Ilivitsky V, Jones BD. Huntington's disease: pathogenesis, diagnosis and treatment. Journal of Psychiatry & Neuroscience : Jpn. 19: 359-67. PMID 7528535  0.48
1993 Randolph C, Mohr E, Chase TN. Assessment of intellectual function in dementing disorders: validity of WAIS-R short forms for patients with Alzheimer's, Huntington's, and Parkinson's disease. Journal of Clinical and Experimental Neuropsychology. 15: 743-53. PMID 8276933 DOI: 10.1080/01688639308402593  0.48
1992 Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Grimes JD, Chase TN. Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 19: 163-9. PMID 1623440 DOI: 10.1017/S0317167100042207  0.48
1992 Vezina P, Mohr E, Grimes D. Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 19: 142-6. PMID 1571860 DOI: 10.1017/S0317167100041524  0.48
1992 Mann UM, Mohr E, Gearing M, Chase TN. Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. Journal of Neurology, Neurosurgery, and Psychiatry. 55: 956-9. PMID 1431960 DOI: 10.1136/jnnp.55.10.956  0.48
1991 Claus JJ, Mohr E, Chase TN. Clinical trials in dementia: learning effects with repeated testing. Journal of Psychiatry & Neuroscience : Jpn. 16: 1-4. PMID 2049365  0.48
1991 Claus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN. Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology. 41: 570-4. PMID 2011259  0.48
1991 Litvan I, Mohr E, Williams J, Gomez C, Chase TN. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 54: 25-9. PMID 2010755  0.48
1991 Mohr E, Brouwers P, Claus JJ, Mann UM, Fedio P, Chase TN. Visuospatial cognition in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 127-32. PMID 1829137 DOI: 10.1002/mds.870060207  0.48
1991 Fedio P, Mohr E. [174] Cognitive and emotional profile of neuropsychiatric disorders Journal of Rehabilitation Research and Development. 28: 145-146.  0.48
1990 Mohr E, Juncos J, Cox C, Litvan I, Fedio P, Chase TN. Selective deficits in cognition and memory in high-functioning parkinsonian patients. Journal of Neurology, Neurosurgery, and Psychiatry. 53: 603-6. PMID 2391526  0.48
1990 Mohr E, Cox C, Williams J, Chase TN, Fedio P. Impairment of central auditory function in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology. 12: 235-46. PMID 2341553 DOI: 10.1080/01688639008400970  0.48
1990 Mohr E, Litvan I, Williams J, Fedio P, Chase TN. Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 17: 292-7. PMID 2207883  0.48
1990 Mohr E, Carter C, Wallin A. Neurochemical substrates of human aging and dementia. Pharmacopsychiatry. 23: 53-5. PMID 2186413 DOI: 10.1055/s-2007-1014533  0.48
1990 Goldberg TE, Berman KF, Mohr E, Weinberger DR. Regional cerebral blood flow and cognitive function in Huntington's disease and schizophrenia. A comparison of patients matched for performance on a prefrontal-type task. Archives of Neurology. 47: 418-22. PMID 2138883 DOI: 10.1001/archneur.1990.00530040062020  0.48
1990 Mohr E, Mann UM, Chase TN. Subgroups in Alzheimer's disease: fact or fiction? Psychiatric Journal of the University of Ottawa : Revue De Psychiatrie De L'Université D'Ottawa. 15: 203-6. PMID 1980952  0.48
1989 Brouwers P, Mohr E. A metric for the evaluation of change in clinical trials. Clinical Neuropharmacology. 12: 129-33. PMID 2720698  0.48
1989 Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, Claus JJ, Fedio P, Chase TN. Clonidine treatment of Alzheimer's disease. Archives of Neurology. 46: 376-8. PMID 2650662 DOI: 10.1001/archneur.1989.00520400030015  0.48
1989 Mann UM, Mohr E, Chase TN. Rapidly progressive Alzheimer's disease. Lancet. 2: 799. PMID 2571032 DOI: 10.1016/S0140-6736(89)90857-X  0.48
1989 Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 631-5. PMID 2567345  0.48
1989 Schlegel J, Mohr E, Williams J, Mann U, Gearing M, Chase TN. Guanfacine treatment of Alzheimer's disease. Clinical Neuropharmacology. 12: 124-8. PMID 2566381  0.48
1989 Mohr E, Fabbrini G, Williams J, Schlegel J, Cox C, Fedio P, Chase TN. Dopamine and memory function in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 4: 113-20. PMID 2543918 DOI: 10.1002/mds.870040202  0.48
1988 Mouradian MM, Mohr E, Williams JA, Chase TN. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology. 38: 606-8. PMID 3281057  0.48
1988 Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Annals of Neurology. 24: 366-71. PMID 3228270 DOI: 10.1002/ana.410240303  0.48
1987 Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN. Cognitive concomitants of dopamine system stimulation in parkinsonian patients. Journal of Neurology, Neurosurgery, and Psychiatry. 50: 1192-6. PMID 3668568 DOI: 10.1136/jnnp.50.9.1192  0.48
1987 Mohr E. Cognitive style and order of recall effects in dichotic listening. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 23: 223-36. PMID 3608518  0.48
1987 Chase TN, Burrows GH, Mohr E. Cortical glucose utilization patterns in primary degenerative dementias of the anterior and posterior type. Archives of Gerontology and Geriatrics. 6: 289-97. PMID 2446576 DOI: 10.1016/0167-4943(87)90028-8  0.48
1986 Bruno G, Mohr E, Gillespie M, Fedio P, Chase TN. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Archives of Neurology. 43: 659-61. PMID 3524514 DOI: 10.1001/archneur.1986.00520070017009  0.48
1986 Mouradian MM, Farah JM, Mohr E, Fabbrini G, O'Donohue TL, Chase TN. Spinal fluid CRF reduction in Alzheimer's disease. Neuropeptides. 8: 393-400. PMID 3493444 DOI: 10.1016/0143-4179(86)90010-7  0.48
1986 Shults C, Steardo L, Barone P, Mohr E, Juncos J, Serrati C, Fedio P, Tamminga CA, Chase TN. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology. 36: 1099-102. PMID 2874527  0.48
1986 Mohr E, Bruno G, Foster N, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, Chase TN. GABA-agonist therapy for Alzheimer's disease. Clinical Neuropharmacology. 9: 257-63. PMID 2872956  0.48
1985 Mohr E, Costa L. Ear asymmetries in dichotic listening tasks which increase in difficulty. Brain and Language. 24: 233-45. PMID 3978405 DOI: 10.1016/0093-934X(85)90133-6  0.48
1981 Mohr E, Corcoran ME. Depletion of noradrenaline and amygdaloid kindling. Experimental Neurology. 72: 507-11. PMID 7238705 DOI: 10.1016/0014-4886(81)90240-5  0.48
Show low-probability matches.